Lyell Immunopharma, Inc. (NASDAQ:LYEL) Director Sumant Ramachandra Acquires 200,000 Shares

Lyell Immunopharma, Inc. (NASDAQ:LYEL) Director Sumant Ramachandra bought 200,000 shares of the stock in a transaction dated Friday, March 21st. The shares were acquired at an average price of $0.58 per share, for a total transaction of $116,000.00. Following the completion of the transaction, the director now owns 200,000 shares of the company’s stock, valued at approximately $116,000. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Lyell Immunopharma Stock Down 6.1 %

LYEL opened at $0.53 on Wednesday. Lyell Immunopharma, Inc. has a 52 week low of $0.48 and a 52 week high of $3.15. The business has a 50 day moving average price of $0.61 and a two-hundred day moving average price of $0.87. The company has a market cap of $155.05 million, a PE ratio of -0.66 and a beta of -0.41.

Lyell Immunopharma (NASDAQ:LYEL) last released its quarterly earnings results on Wednesday, March 12th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.52). Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. The company had revenue of $0.01 million for the quarter. As a group, sell-side analysts expect that Lyell Immunopharma, Inc. will post -0.78 EPS for the current fiscal year.

Institutional Trading of Lyell Immunopharma

Several hedge funds have recently made changes to their positions in the company. Decheng Capital LLC acquired a new position in shares of Lyell Immunopharma during the fourth quarter worth about $7,622,000. Foresite Capital Management V LLC acquired a new position in Lyell Immunopharma during the 4th quarter worth approximately $5,205,000. venBio Partners LLC purchased a new position in shares of Lyell Immunopharma during the 4th quarter worth approximately $4,545,000. Geode Capital Management LLC lifted its holdings in shares of Lyell Immunopharma by 2.9% in the 4th quarter. Geode Capital Management LLC now owns 4,137,264 shares of the company’s stock valued at $2,648,000 after buying an additional 117,303 shares during the period. Finally, State Street Corp lifted its holdings in shares of Lyell Immunopharma by 1.9% in the 3rd quarter. State Street Corp now owns 3,889,553 shares of the company’s stock valued at $5,368,000 after buying an additional 71,233 shares during the period. Institutional investors and hedge funds own 66.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “neutral” rating and set a $1.00 price objective on shares of Lyell Immunopharma in a research report on Thursday, March 13th.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.